<!DOCTYPE html>
<html>
<head>
    <title>BREAKING: Federal Register: Requests for Reconsideration at the Division Level Under the Generic Drug User Fee Amendments; Draft Guidance for Industry; Availability; Agency Information Collection Activities; Proposed Collection; Comment Request</title>
    <meta charset="UTF-8">
    <style>
        body { font-family: Georgia, serif; max-width: 800px; margin: 0 auto; padding: 20px; }
        h1 { border-bottom: 2px solid #333; }
        .breaking { background: #fff3cd; border-left: 4px solid #dc3545; padding: 15px; }
        .source { background: #f8f9fa; padding: 10px; margin-top: 20px; font-size: 0.9em; }
        .timestamp { color: #666; }
    </style>
</head>
<body>
    <h1>BREAKING: Federal Register: Requests for Reconsideration at the Division Level Under the Generic Drug User Fee Amendments; Draft Guidance for Industry; Availability; Agency Information Collection Activities; Proposed Collection; Comment Request</h1>
    <p class="timestamp">Published: 2024-01-11 | Source: Federal Register</p>
    <div class="breaking">
        <p><strong>The Food and Drug Administration (FDA, Agency, or we) is announcing the availability of a draft guidance for industry entitled "Requests for Reconsideration at the Division Level Under GDUFA." This draft guidance provides recommendations on the procedures for applicants of abbreviated new drug applications (ANDAs) that wish to pursue a request for reconsideration within the review discipline at the division level or original signatory authority. This draft guidance revises the draft guidance of ...</strong></p>
    </div>
    <h2>Document Details</h2>
    <p><strong>Document Type:</strong> Notice</p>
    <p><strong>Agency:</strong> Health and Human Services Department, Food and Drug Administration</p>
    <p><strong>Document Number:</strong> 2024-00403</p>
    <p><strong>Publication Date:</strong> 2024-01-11</p>
    <h2>Official Source</h2>
    <p>Read the full document at: <a href="https://www.federalregister.gov/documents/2024/01/11/2024-00403/requests-for-reconsideration-at-the-division-level-under-the-generic-drug-user-fee-amendments-draft">https://www.federalregister.gov/documents/2024/01/11/2024-00403/requests-for-reconsideration-at-the-division-level-under-the-generic-drug-user-fee-amendments-draft</a></p>
    <div class="source"><strong>Source:</strong> Federal Register - 2024-00403</div>
    <p><a href="index.html">Back to Breaking News Wire</a></p>
</body>
</html>
